Geron Corp (GERN) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. FIS
3. BROS
4. ARM
5. EXPE
6. QCOM
7. DDOG
8. CHYM
9. CPAY
10. PAYC

Go back to Geron Corp (GERN) Misses Q1 EPS by 1c

Geron Corporation Reports First Quarter 2021 Financial Results and Recent Highlights

May 10, 2021 4:05 PM EDT

IMerge Phase 3 Clinical Trial in Myelodysplastic Syndromes 75% Enrolled and On Track to Complete Enrollment in Second Half of 2021

Two Abstracts Accepted by European Hematology Association for 2021 Virtual Congress

Conference Call Scheduled for 4:30 p.m. ET Today

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reported financial results for the first quarter ended March 31, 2021, as well as company highlights and... More